Evidence map›Paper›PMID 39904775›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data.

Hiroshi Inano, Yoshihito Morimoto, Kanata Kitagawa, Akito Shibuya, Kozue Nakagomi, Tomohiro Ota, Yuri Anzo, Rika Miyauchi, Aiko Shono, Kazuhiro Watanabe and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroshi InanoDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.ORCID http://orcid.org/0000-0003-1921-9822
Yoshihito MorimotoEducation and Research Center for Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan. y-morimoto@ac.shoyaku.ac.jp.ORCID http://orcid.org/0000-0002-1058-0614
Kanata KitagawaDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.
Akito ShibuyaDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.
Kozue NakagomiDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.
Tomohiro OtaDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.
Yuri AnzoDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.
Rika MiyauchiEducation and Research Center for Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan.
Aiko ShonoLaboratory of Public Health, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan.
Kazuhiro WatanabeEducation and Research Center for Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan.
Katsuya OtoriDepartment of Pharmacy, Kitasato University Hospital, 1-15-1, Kitasato, Sagamihara, Minami, 252-0375, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur previous study showed that the preventive effects of fosnetupitant (F-NTP) against chemotherapy-induced nausea and vomiting (CINV) were superior to those of fosaprepitant (F-APR) or aprepitant (APR). To evaluate the cost-effectiveness of F-NTP compared with F-APR or APR in Japan, a cost-utility analysis was performed.

methodsA decision tree model was developed based on real-world data to compare the CINV prevention ability of each neurokinin-1 receptor antagonist (NK

resultsThe incremental QALYs of F-NTP relative to F-APR and APR were 0.00180 and 0.00153, respectively. The ICER of F-NTP relative to F-APR was 22,802.21 US dollars (USD) per QALY gained, which was lower than the willingness-to-pay (WTP) threshold (38,043.06 USD: 5 million Japanese Yen/QALY). Contrastingly, the ICER of F-NTP relative to APR was 40,119.64 USD/QALY, which was slightly above the WTP threshold, indicating that F-NTP may be slightly less cost-effective.

conclusionF-NTP is more cost-effective than F-APR, but slightly less cost-effective than APR.

Indexed as

AntiemeticsAntineoplastic AgentsCisplatinMorpholinesNauseaVomitingAprepitantCost-Benefit AnalysisCost-Effectiveness AnalysisDecision TreesFemaleHumansJapanMaleQuality-Adjusted Life YearsAntiemeticsAntineoplastic AgentsAprepitantCisplatinfosaprepitantMorpholinesChemotherapyCINVCost-effectivenessFosnetupitantNauseaNK1 RA

Identifiers

PMID39904775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.